The recipient of a law degree from the University Of Miami School Of Law, David Simon balances a busy career as a senior executive at Twin Capital Management, LLC, with a commitment to charity. In addition to running his own foundation, David Simon gives back through various initiatives such as co-sponsoring an annual charity dinner benefitting Solving Kids’ Cancer (SKC).
Founded with the motto “Every Kid Deserves to Grow Up,” SKC is a nonprofit group focused on aggressive and deadly childhood cancers, an oft-neglected area of research and support. To promote its mission, SKC identifies and provides funding and advocacy for cutting-edge treatments for these illnesses.
Since it launched in 2007, SKC has helped to fund nearly three dozen pediatric cancer research projects in countries around the world while collaborating with other charitable groups to support 19 more. The projects have focused on immunotherapy, neuroblastoma, brain tumors, and sarcoma research.
Among other successful initiatives, in 2016 SKC joined two other nonprofit groups to fund a Phase I clinical trial exploring the use of combination checkpoint inhibitors in children with brain tumors. Although the trial was initially limited to four US locations, pharmaceutical company Bristol-Myers Squibb quickly saw the promise in the research and lent its support. As a result, the trial expanded to nearly 60 centers across 13 countries while moving into Phase II, bringing new hope to a generation of children with brain tumors.
Founded with the motto “Every Kid Deserves to Grow Up,” SKC is a nonprofit group focused on aggressive and deadly childhood cancers, an oft-neglected area of research and support. To promote its mission, SKC identifies and provides funding and advocacy for cutting-edge treatments for these illnesses.
Since it launched in 2007, SKC has helped to fund nearly three dozen pediatric cancer research projects in countries around the world while collaborating with other charitable groups to support 19 more. The projects have focused on immunotherapy, neuroblastoma, brain tumors, and sarcoma research.
Among other successful initiatives, in 2016 SKC joined two other nonprofit groups to fund a Phase I clinical trial exploring the use of combination checkpoint inhibitors in children with brain tumors. Although the trial was initially limited to four US locations, pharmaceutical company Bristol-Myers Squibb quickly saw the promise in the research and lent its support. As a result, the trial expanded to nearly 60 centers across 13 countries while moving into Phase II, bringing new hope to a generation of children with brain tumors.
